Related references
Note: Only part of the references are listed.HMGB1-mediated restriction of EPO signaling contributes to anemia of inflammation
Brian M. Dulmovits et al.
BLOOD (2022)
Relapsed classic Hodgkin lymphoma with decreased CD30 expression after brentuximab and anti-CD30 CAR-T therapies
Do Hwan Kim et al.
BLOOD (2022)
Clinical Impact of Immune Cells and Their Spatial Interactions in Diffuse Large B-Cell Lymphoma Microenvironment
Matias Autio et al.
CLINICAL CANCER RESEARCH (2022)
FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma
Poornima Sharma et al.
CLINICAL CANCER RESEARCH (2022)
Adoptive T cell therapy of solid tumors: time to team up with immunogenic chemo/radiotherapy
Arianna Pocaterra et al.
CURRENT OPINION IN IMMUNOLOGY (2022)
High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma
Yuanyan Tang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)
A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb
Yang Wu et al.
CANCER GENE THERAPY (2022)
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
Caron A. Jacobson et al.
LANCET ONCOLOGY (2022)
Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells
J. Joseph Melenhorst et al.
NATURE (2022)
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
Nathan Hale Fowler et al.
NATURE MEDICINE (2022)
A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers
Derek P. Wong et al.
NATURE COMMUNICATIONS (2022)
Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and revies of the literature
Guoxing Zhao et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)
Armored BCMA CAR T Cells Eliminate Multiple Myeloma and Are Resistant to the Suppressive Effects of TGF-β
Leah M. Alabanza et al.
FRONTIERS IN IMMUNOLOGY (2022)
Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)
Marc Wehrli et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy
Krishna R. Juluri et al.
BLOOD ADVANCES (2022)
Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma
Timothy J. Voorhees et al.
BLOOD ADVANCES (2022)
CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies
Timothy N. J. Bullock
CELLULAR & MOLECULAR IMMUNOLOGY (2022)
Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia
Paul M. Maciocia et al.
BLOOD (2022)
Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis
Ricardo D. Parrondo et al.
BLOOD CANCER JOURNAL (2022)
Superior antitumor immunotherapy efficacy of kynureninase modified CAR-T cells through targeting kynurenine metabolism
Quanjun Yang et al.
ONCOIMMUNOLOGY (2022)
Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia
Saar Gill et al.
BLOOD ADVANCES (2022)
Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy
Emma C. Morris et al.
NATURE REVIEWS IMMUNOLOGY (2022)
CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T cells
Marika Guercio et al.
HAEMATOLOGICA (2021)
Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges
Binod Dhakal et al.
BONE MARROW TRANSPLANTATION (2021)
Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma
Paolo Strati et al.
HAEMATOLOGICA (2021)
Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies
Takayuki Ikezoe
INTERNATIONAL JOURNAL OF HEMATOLOGY (2021)
Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint
TingTing Tang et al.
PHARMACOLOGY & THERAPEUTICS (2021)
CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia
Guozhu Xie et al.
NATURE BIOMEDICAL ENGINEERING (2021)
A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma
Di Wang et al.
BLOOD (2021)
Preclinical and clinical advances in dual-target chimeric antigen receptor therapy for hematological malignancies
Zhenling Guo et al.
CANCER SCIENCE (2021)
Eradication of T-ALL Cells by CD7-targeted Universal CAR-T Cells and Initial Test of Ruxolitinib-based CRS Management
Shiqi Li et al.
CLINICAL CANCER RESEARCH (2021)
The blood-brain barrier in systemic infection and inflammation
Ian Galea
CELLULAR & MOLECULAR IMMUNOLOGY (2021)
Cytotoxic effect of CLL-1 CAR-T cell immunotherapy with PD-1 silencing on relapsed/refractory acute myeloid leukemia
Guoqiang Lin et al.
MOLECULAR MEDICINE REPORTS (2021)
Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide
Max Jan et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
DAMPs released by pyroptotic cells as major contributors and therapeutic targets for CAR-T-related toxicities
Tian Deng et al.
CELL DEATH & DISEASE (2021)
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
Heng Mei et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity
Jiangzhou Shi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Prognostic Significance of Cytokine Release Syndrome in B Cell Hematological Malignancies Patients After Chimeric Antigen Receptor T Cell Therapy
Rujiao Dong et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2021)
Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma
John H. Baird et al.
BLOOD ADVANCES (2021)
Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML
Martin Wermke et al.
BLOOD (2021)
CRS-related coagulopathy in BCMA targeted CAR-T therapy: a retrospective analysis in a phase I/II clinical trial
Mi Shao et al.
BONE MARROW TRANSPLANTATION (2021)
B-Cell Lymphomas, Version 5.2021 Featured Updates to the NCCN Guidelines
Andrew D. Zelenetz et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy
Jessica Wenthe et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
An orthogonal IL-2 and IL-2Rβ system drives persistence and activation of CART cells and clearance of bulky lymphoma
Paul-Joseph Aspuria et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
A human orthogonal IL-2 and IL-2Rβ system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia
Qian Zhang et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
Mehmet Kemal Samur et al.
NATURE COMMUNICATIONS (2021)
Direct control of CAR T cells through small molecule-regulated antibodies
Spencer Park et al.
NATURE COMMUNICATIONS (2021)
Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia
Nadia El Khawanky et al.
NATURE COMMUNICATIONS (2021)
The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma
Deming Duan et al.
FRONTIERS IN IMMUNOLOGY (2021)
Viral infection/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy
Di Wang et al.
BLOOD CANCER JOURNAL (2021)
A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia
Chunrui Li et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2021)
CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity
Tim Sauer et al.
BLOOD (2021)
Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma
Meijing Liu et al.
CANCER SCIENCE (2021)
Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of Apoptosis
Lisa C. Holthof et al.
CLINICAL CANCER RESEARCH (2021)
Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials
Yimei Que et al.
FRONTIERS IN IMMUNOLOGY (2021)
CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma
Sabrina Prommersberger et al.
GENE THERAPY (2021)
4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells
Emiliano Roselli et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Case Report: Sirolimus Alleviates Persistent Cytopenia After CD19 CAR-T-Cell Therapy
Limin Xing et al.
FRONTIERS IN ONCOLOGY (2021)
The Bone Marrow Microenvironment Mechanisms in Acute Myeloid Leukemia
Debora Bifano Pimenta et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia
Francesco Paolo Tambaro et al.
LEUKEMIA (2021)
Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models
Dina Schneider et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
A novel full-human CD22-CAR T cell therapy with potent activity against CD22low B-ALL
Yue Tan et al.
BLOOD CANCER JOURNAL (2021)
CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma
Kai Rejeski et al.
BLOOD (2021)
Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia
Hardikkumar Jetani et al.
BLOOD (2021)
Chimeric antigen receptor T cells targeting CD7 in a child with high-risk T-cell acute lymphoblastic leukemia
Lichun Xie et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2021)
Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia
Regina M. Myers et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial
Jing Pan et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
Qingya Cui et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
Jesus G. Berdeja et al.
LANCET (2021)
A novel and efficient tandem CD19- and CD22-directed CAR for B-cell ALL
Samanta Romina Zanetti et al.
MOLECULAR THERAPY (2021)
Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) T cells for CD19-positive malignancies
Sanmei Wang et al.
ONCOLOGY REPORTS (2021)
Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy
Haibo Zhu et al.
ONCOTARGETS AND THERAPY (2021)
CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study
Guoqing Wei et al.
CANCER IMMUNOLOGY RESEARCH (2021)
Risk of HBV Reactivation in Patients With Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis
Ping Li et al.
FRONTIERS IN IMMUNOLOGY (2021)
Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease
Haobin Deng et al.
FRONTIERS IN IMMUNOLOGY (2021)
CAR T-cell therapy for multiple myeloma: state of the art and prospects
Niels W C J van de Donk et al.
Lancet Haematology (2021)
Thrombopoietin receptor agonists for acquired thrombocytopenia following anti-CD19 CAR-T-cell therapy: a case report
Rebecca Baur et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
IL-15 Enhances the Persistence and Function of BCMA-Targeting CAR-T Cells Compared to IL-2 or IL-15/IL-7 by Limiting CAR-T Cell Dysfunction and Differentiation
Anthony M. Battram et al.
CANCERS (2021)
Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy
Andrew Johnsrud et al.
BLOOD ADVANCES (2021)
Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML
Jan-Erik Meyer et al.
ONCOIMMUNOLOGY (2021)
The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma
Albert Oriol et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2021)
Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression
Evripidis Lanitis et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2021)
B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies
Larysa Sanchez et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2021)
Treatment of Aggressive T Cell Lymphoblastic Lymphoma/leukemia Using Anti-CD5 CAR T Cells
Jia Feng et al.
STEM CELL REVIEWS AND REPORTS (2021)
The nuclear export protein XPO1-from biology to targeted therapy
Asfar S. Azmi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Coagulation Disorders after Chimeric Antigen Receptor T Cell Therapy: Analysis of 100 Patients with Relapsed and Refractory Hematologic Malignancies
Ying Wang et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
The immune landscape and response to immune checkpoint blockade therapy in lymphoma
Justin Kline et al.
BLOOD (2020)
Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure
Jordan Gauthier et al.
BLOOD (2020)
Selinexor-based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy
Ajai Chari et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
Nina Shah et al.
LEUKEMIA (2020)
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Enli Liu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide
Sabarinath V. Radhakrishnan et al.
NATURE COMMUNICATIONS (2020)
Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30+ lymphoma patients
D. Wang et al.
BLOOD CANCER JOURNAL (2020)
Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia
Shuangyou Liu et al.
BLOOD CANCER JOURNAL (2020)
A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy
Rebecca Epperly et al.
FRONTIERS IN ONCOLOGY (2020)
Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome
Yuying Liu et al.
SCIENCE IMMUNOLOGY (2020)
Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
Maria-Luisa Schubert et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40
Jessica Wenthe et al.
CANCER GENE THERAPY (2020)
Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies
Wenting Song et al.
CLINICAL IMMUNOLOGY (2020)
Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma
Christopher M. Wright et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
Hanren Dai et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
In Vivo Generation of CAR T Cells Selectively in Human CD4+ Lymphocytes
Shiwani Agarwal et al.
MOLECULAR THERAPY (2020)
Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia
Simon Loff et al.
MOLECULAR THERAPY-ONCOLYTICS (2020)
Challenges for Immunotherapy in Multiple Myeloma: Bone Marrow Microenvironment-Mediated Immune Suppression and Immune Resistance
Lisa C. Holthof et al.
CANCERS (2020)
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma
Chuan Tong et al.
BLOOD (2020)
How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies
Joshua A. Hill et al.
BLOOD (2020)
Phase II trial of co-administration of CD19-and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma
Wei Sang et al.
CANCER MEDICINE (2020)
Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia
Meir Rozenbaum et al.
FRONTIERS IN IMMUNOLOGY (2020)
41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo
Matteo Libero Baroni et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity
Jia Wei et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma
Carlos A. Ramos et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma
Chelsea C. Pinnix et al.
BLOOD ADVANCES (2020)
Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma
Paolo Strati et al.
BLOOD ADVANCES (2020)
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies
Tania Jain et al.
BLOOD ADVANCES (2020)
Macrophage, the potential key mediator in CAR-T related CRS
Zhaonian Hao et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2020)
Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19
Eugenio D. Hottz et al.
BLOOD (2020)
Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery
Cesar Sommer et al.
MOLECULAR THERAPY (2020)
Synergistic effect of ibrutinib and CD19 CAR-T cells on Raji cells in vivo and in vitro
Meijing Liu et al.
CANCER SCIENCE (2020)
Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents
Carsten Riether et al.
NATURE MEDICINE (2020)
Inducible secretion of IL-21 augments anti-tumor activity of piggyBac-manufactured chimeric antigen receptor T cells
Martin Stach et al.
CYTOTHERAPY (2020)
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Jeremy S. Abramson et al.
LANCET (2020)
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas
Qing Deng et al.
NATURE MEDICINE (2020)
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial
Nirav N. Shah et al.
NATURE MEDICINE (2020)
Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-Cells
Liangshun You et al.
FRONTIERS IN IMMUNOLOGY (2020)
Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus
Lu Han et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Cytokines in CAR T Cell-Associated Neurotoxicity
Juliane Gust et al.
FRONTIERS IN IMMUNOLOGY (2020)
Successful 24-Hours Manufacture of Anti-CD19/CD22 Dual Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia (BALL)
Junfang Yang et al.
BLOOD (2020)
Sustained Remission of Relapsed or Refractory Mantle Cell Lymphoma After 4-1BB-Based CD19-Directed CAR-T Therapy
Chunmei Yang et al.
ONCOTARGETS AND THERAPY (2020)
The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma
Jianshu Wei et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome
Puja Mehta et al.
LANCET RHEUMATOLOGY (2020)
Characterization of an Anti-CD5 Directed CAR T-Cell against T-Cell Malignancies
Masayuki Wada et al.
STEM CELL REVIEWS AND REPORTS (2020)
DAMP-sensing receptors in sterile inflammation and inflammatory diseases
Tao Gong et al.
NATURE REVIEWS IMMUNOLOGY (2020)
The gasdermins, a protein family executing cell death and inflammation
Petr Broz et al.
NATURE REVIEWS IMMUNOLOGY (2020)
2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma
Sattva S. Neelapu et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Early and late hematologic toxicity following CD19 CAR-T cells
Shalev Fried et al.
BONE MARROW TRANSPLANTATION (2019)
CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response
Nicholas F. Kuhn et al.
CANCER CELL (2019)
Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma
Moo-Kon Song et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators
Mohit Sachdeva et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape
Mohamad Hamieh et al.
NATURE (2019)
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells
Eric L. Smith et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma
Chuang Sun et al.
Oncotarget (2019)
IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype
Darya Alizadeh et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy
Huiwen Jiang et al.
ANNALS OF HEMATOLOGY (2019)
Chimeric antigen receptor T cell persistence and memory cell formation
Alexander D. McLellan et al.
IMMUNOLOGY AND CELL BIOLOGY (2019)
CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia
Jing Pan et al.
LEUKEMIA (2019)
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Effect and changes in PD-1 expression of CD19 CAR-T cells from T cells highly expressing PD-1 combined with reduced-dose PD-1 inhibitor
Rui Zhang et al.
ONCOLOGY REPORTS (2019)
leExploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma
Jie Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy
Eric L. Smith et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma
Austin J. Sim et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma
Sujun Li et al.
ONCOTARGETS AND THERAPY (2019)
Chimeric antigen receptor T (CAR-T) cells expanded with IL-7/IL-15 mediate superior antitumor effects
Jianxia Zhou et al.
PROTEIN & CELL (2019)
γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma
Margot J. Pont et al.
BLOOD (2019)
Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T cell Function against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide
Melissa Works et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Anemia of Inflammation
Tomas Ganz
NEW ENGLAND JOURNAL OF MEDICINE (2019)
CAR-T 19 combined with reduced-dose PD-1 blockade therapy for treatment of refractory follicular lymphoma: A case report
Jia Wang et al.
ONCOLOGY LETTERS (2019)
Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma
Yaqing Cao et al.
FRONTIERS IN ONCOLOGY (2019)
Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy
Hui Luo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts
Rosalie M. Sterner et al.
BLOOD (2019)
A retrospective comparison of allogenic and autologous chimeric antigen receptor T cell therapy targeting CD19 in patients with relapsed/refractory acute lymphoblastic leukemia
Yongxian Hu et al.
BONE MARROW TRANSPLANTATION (2019)
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
Steven Horwitz et al.
LANCET (2019)
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke et al.
LANCET ONCOLOGY (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma
Andrea Schmidts et al.
BLOOD ADVANCES (2019)
Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations
Robert Weinkove et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2019)
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Terry J. Fry et al.
NATURE MEDICINE (2018)
Concise Review: Emerging Principles from the Clinical Application of Chimeric Antigen Receptor T Cell Therapies for B Cell Malignancies
Michael D. Jain et al.
STEM CELLS (2018)
Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas
Michelle A. Fanale et al.
BLOOD (2018)
The potential role of gamma delta T cells after allogeneic HCT for leukemia
Rupert Handgretinger et al.
BLOOD (2018)
Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells
Jae H. Park et al.
CLINICAL INFECTIOUS DISEASES (2018)
CD4 Helper and CD8 Cytotoxic T Cell Differentiation
Ichiro Taniuchi
ANNUAL REVIEW OF IMMUNOLOGY, VOL 36 (2018)
CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia
Jinghua Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
CAR T-cells targeting FLT3 have potent activity against FLT3(-)ITD(+) AML and act synergistically with the FLT3-inhibitor crenolanib
Hardikkumar Jetani et al.
LEUKEMIA (2018)
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
Margherita Norelli et al.
NATURE MEDICINE (2018)
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Theodoros Giavridis et al.
NATURE MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
Bianca D. Santomasso et al.
CANCER DISCOVERY (2018)
Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates
Agne Taraseviciute et al.
CANCER DISCOVERY (2018)
IL-21 modulates memory and exhaustion phenotype of T-cells in a fatty acid oxidation-dependent manner
Romy Loschinski et al.
Oncotarget (2018)
Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System
Mauro P. Avanzi et al.
CELL REPORTS (2018)
Human γδ T-Cells: From Surface Receptors to the Therapy of High-Risk Leukemias
Vito Pistoia et al.
FRONTIERS IN IMMUNOLOGY (2018)
In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome
Anett Pfeiffer et al.
EMBO MOLECULAR MEDICINE (2018)
A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML
Samuel John et al.
MOLECULAR THERAPY (2018)
Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape
Carl DeSelm et al.
MOLECULAR THERAPY (2018)
In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas
Carlos A. Ramos et al.
MOLECULAR THERAPY (2018)
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
Sarwish Rafiq et al.
NATURE BIOTECHNOLOGY (2018)
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
Marco Ruella et al.
NATURE MEDICINE (2018)
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
Elena J. Orlando et al.
NATURE MEDICINE (2018)
Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies
Juliane Gust et al.
CNS DRUGS (2018)
CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells
Marion Alcantara et al.
LEUKEMIA (2018)
4-1BB enhancement of CAR T function requires NF-κB and TRAFs
Gongbo Li et al.
JCI INSIGHT (2018)
An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma
Lydia Lee et al.
BLOOD (2018)
Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy
Joshua A. Hill et al.
BLOOD (2018)
Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial
Chun-Meng Wang et al.
CLINICAL CANCER RESEARCH (2017)
Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes
Carlos A. Ramos et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche
Fotis Asimakopoulos et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2017)
High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients
J. Pan et al.
LEUKEMIA (2017)
Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells
Iulia Diaconu et al.
MOLECULAR THERAPY (2017)
Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies
Paul M. Maciocia et al.
NATURE MEDICINE (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells
Marco Ruella et al.
CANCER DISCOVERY (2017)
CNS Endothelial Cell Activation Emerges as a Driver of CAR T Cell-Associated Neurotoxicity
Crystal L. Mackall et al.
CANCER DISCOVERY (2017)
Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
Thomas Shum et al.
CANCER DISCOVERY (2017)
Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
Juliane Gust et al.
CANCER DISCOVERY (2017)
SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes
Tea Gogishvili et al.
BLOOD (2017)
Long-term safety and efficacy of CART-20 cells in patients with refractory or relapsed B-cell non-Hodgkin lymphoma: 5-years follow-up results of the phase I and IIa trials
Wen-ying Zhang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2017)
Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights
Amrom E. Obstfeld et al.
BLOOD (2017)
Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus
Emma Eriksson et al.
CLINICAL CANCER RESEARCH (2017)
Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts
Jessica Hartmann et al.
EMBO MOLECULAR MEDICINE (2017)
Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function
Nathan Singh et al.
CYTOTHERAPY (2017)
Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells
K. Pinz et al.
LEUKEMIA (2016)
Identification of PD1 and TIM3 As Checkpoints That Limit Chimeric Antigen Receptor T Cell Efficacy in Leukemia
Saad S. Kenderian et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer
Vishwajith Sridharan et al.
BRITISH JOURNAL OF CANCER (2016)
Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
Esther Drent et al.
HAEMATOLOGICA (2016)
Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
Niels W. C. J. van de Donk et al.
IMMUNOLOGICAL REVIEWS (2016)
Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia
Paulina J. Paszkiewicz et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients
Cameron J. Turtle et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
Yongxian Hu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity
Elad Jacoby et al.
NATURE COMMUNICATIONS (2016)
Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
Esther Drent et al.
HAEMATOLOGICA (2016)
The intersection of radiotherapy and immunotherapy: Mechanisms and clinical implications
Michael Spiotto et al.
SCIENCE IMMUNOLOGY (2016)
γδ T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-αβ+/CD19+ lymphocytes
Irma Airoldi et al.
BLOOD (2015)
Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells
Zeguo Zhao et al.
CANCER CELL (2015)
Pivotal Roles of GM-CSF in Autoimmunity and Inflammation
Aoi Shiomi et al.
MEDIATORS OF INFLAMMATION (2015)
Enhancing Antitumor Efficacy of Chimeric Antigen Receptor T Cells Through Constitutive CD40L Expression
Kevin J. Curran et al.
MOLECULAR THERAPY (2015)
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
Adrienne H. Long et al.
NATURE MEDICINE (2015)
Remote control of therapeutic T cells through a small molecule-gated chimeric receptor
Chia-Yung Wu et al.
SCIENCE (2015)
Individual Motile CD4+ T Cells Can Participate in Efficient Multikilling through Conjugation to Multiple Tumor Cells
Ivan Liadi et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Co-expression of CD40/CD40L On XG1 Multiple Myeloma Cells Promotes IL-6 Autocrine Function
Chunjian Qi et al.
CANCER INVESTIGATION (2015)
Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells
Yao Wang et al.
CLINICAL IMMUNOLOGY (2014)
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2014)
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
Waleed Haso et al.
BLOOD (2013)
IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors
Nicoletta Cieri et al.
BLOOD (2013)
T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment
Joel Crespo et al.
CURRENT OPINION IN IMMUNOLOGY (2013)
Rewiring cancer cell death to enhance oncolytic viro-immunotherapy
Samuel T. Workenhe et al.
ONCOIMMUNOLOGY (2013)
Blockade of PD-1 immunosuppression boosts CAR T-cell therapy
Liza B. John et al.
ONCOIMMUNOLOGY (2013)
Tumor cell recognition by γδ T lymphocytes T-cell receptor vs. NK-cell receptors
Daniel V. Correia et al.
ONCOIMMUNOLOGY (2013)
Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma
Djordje Atanackovic et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
An Interleukin-21-Interleukin-10-STAT3 Pathway Is Critical for Functional Maturation of Memory CD8+ T Cells
Weiguo Cui et al.
IMMUNITY (2011)
The CD40/CD40 ligand interactions exert pleiotropic effects on bone marrow granulopoiesis
Irene Mavroudi et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2011)
Upregulation of tissue factor in monocytes by cleaved high molecular weight kininogen is dependent on TNF-α and IL-1β
Mohammad M. Khan et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2010)
The MHC class Ib protein ULBP1 is a nonredundant determinant of leukemia/lymphoma susceptibility to γδ T-cell cytotoxicity
Telma Lanca et al.
BLOOD (2010)
Blockade of IL-15 Activity Inhibits Microglial Activation Through the NFκB, p38, and ERK1/2 Pathways, Reducing Cytokine and Chemokine Release
Diego Gomez-Nicola et al.
GLIA (2010)
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety
V. Hoyos et al.
LEUKEMIA (2010)
Molecular mechanism and function of CD40/CD40L engagement in the immune system
Raul Elgueta et al.
IMMUNOLOGICAL REVIEWS (2009)
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma
Eric D. Hsi et al.
CLINICAL CANCER RESEARCH (2008)
Human Flt3 is expressed at the hematopoietic stem cell and the granulocyte/macrophage progenitor stages to maintain cell survival
Yoshikane Kikushige et al.
JOURNAL OF IMMUNOLOGY (2008)
Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells
W. J. Cao et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis
Eugene D. Ponomarev et al.
JOURNAL OF IMMUNOLOGY (2007)
Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs
Dzung H. Nguyen et al.
EXPERIMENTAL HEMATOLOGY (2006)
A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry
SH Olejniczak et al.
IMMUNOLOGICAL INVESTIGATIONS (2006)
Cutting edge: T cells trigger CD40-dependent platelet activation and granular RANTES release: A novel pathway for immune response amplification
S Danese et al.
JOURNAL OF IMMUNOLOGY (2004)
Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow
A Bernardo et al.
BLOOD (2004)
C-type lectin-like molecule-1: A novel myeloid cell surface marker associated with acute myeloid leukemia
ABH Bakker et al.
CANCER RESEARCH (2004)
CD40 stimulation leads to effective therapy of CD40-tumors through induction of strong systemic cytotoxic T lymphocyte immunity
GJD van Mierlo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines
G Teoh et al.
BLOOD (2000)